Literature DB >> 4042731

Pulmonary gas exchange and exercise performance in pulmonary hypertension.

D R Dantzker, G E D'Alonzo.   

Abstract

Patients with pulmonary hypertension have disordered pulmonary gas exchange and impaired exercise tolerance. The hypoxemia is due to mild ventilation-perfusion (VA/Q) inequality exaggerated by the presence of a low mixed venous PO2 (PvO2) and is accentuated during exercise due to a further fall in PvO2. This in turn may be worsened by vasodilators which increase the degree of VA/Q inequality. Decreased exercise tolerance is due predominantly to cardiac limitation, and thus an improvement in cardiac function subsequent to successful vasodilation can be assessed by improved exercise performance.

Entities:  

Mesh:

Year:  1985        PMID: 4042731     DOI: 10.1378/chest.88.4_supplement.255s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

Review 1.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

2.  Pentoxifylline therapy: a new adjunct in the treatment of pulmonary hypertension?

Authors:  I S Park; R D Leachman
Journal:  Tex Heart Inst J       Date:  1988

3.  Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment.

Authors:  Fabricio Martins Valois; Luiz Eduardo Nery; Roberta Pulcheri Ramos; Eloara Vieira Machado Ferreira; Celia Camelo Silva; Jose Alberto Neder; Jaquelina Sonoe Ota-Arakaki
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

4.  Comprehensive evaluation of complex polymicrobial specimens using next generation sequencing and standard microbiological culture.

Authors:  Lisa A Cummings; Daniel R Hoogestraat; Sara L Rassoulian-Barrett; Christopher A Rosenthal; Stephen J Salipante; Brad T Cookson; Noah G Hoffman
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.